Hvis graviditet forekommer under behandling eller inden for fire måneder efter ophørt behandling, skal patienten informeres om den betydelige teratogene risiko ved ribavirin for fosteret.
If pregnancy does occur during treatment or within four months from stopping treatment, the patient must be advised of the significant teratogenic risk of ribavirin to the foetus.